![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
PITTSBURGH, Sept. 19, 2022 (GLOBE NEWSWIRE) — BlueSphere Bio, a T-cell receptor (TCR) T-cell remedy firm growing a robust TCR discovery platform and novel therapeutic candidates for sufferers with hematologic malignancies and stable tumors, as we speak introduced the firm will current a poster, at the 7th Annual CAR-TCR Summit, being held in Boston, MA from September 19 – 22, 2022. The summit brings collectively over 200 trade leaders to talk about discovery by means of to the commercialization of viable cell therapies.
Title: TCXpress™ and iTCXpress™: A Direct, High-throughput Platform Utilizing Parallel Processes for Efficient and Cost-Effective Discovery and Characterization of Novel TCRs.
Presenters: Jennifer Roy, Associate Scientist, BlueSphere Bio and Stephanie Stras, Associate Scientist, BlueSphere Bio
Date: September 22, 2022
Time: 1:00-2:00pmET
About TCXpress™
TCXpress™ is a proprietary high-throughput and environment friendly T-cell receptor (TCR) seize, expression and practical screening platform able to processing hundreds of single T cells instantly into functionally expressed TCRs inside a matter of days, thereby creating in depth libraries with out the want for prolonged predictive sequencing.
About BlueSphere Bio
BlueSphere Bio is the first translational sciences stand-alone firm shaped by UPMC Enterprises, the innovation, commercialization, and enterprise capital arm of the Pittsburgh-based well being system. The firm was based upon the distinctive, superior TCR discovery platform – TCXpress™, designed to isolate and functionally characterize TCRs with pace and effectivity. BlueSphere anticipates submitting its first IND software in the first quarter of 2023 for a novel TCR T-cell remedy for sufferers with high-risk leukemias, together with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS) in the context of allogeneic stem cell transplantation. Concurrent with its program for hematologic cancers, BlueSphere is deploying TCXpress™ and NEOXpress™, a proprietary patient-specific neoantigen discovery platform, to goal patient-specific neoantigens and anticipates extra digital affected person information from a number of stable tumor sorts over the subsequent a number of months.
Company Contact
Kim Jaffe
Vice President, Business Development & Operations
+1- 609-306-7042
[email protected]
Media Contact
Andrew Mielach
LifeSci Communications
+1-646-876-5868
[email protected]
